NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2.32 mln
Earnings Date09/11/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
35.61
Transformational upside
Relative Strength
4
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
-62.57
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Biodexa Pharmaceuticals is a UK-based clinical-stage company working to develop treatments for conditions including Type 1 diabetes, bladder cancer, and rare brain tumors. Its two main drug candidates, Tolimidone and MTX110, are currently in early-phase clinical trials targeting diabetes and several forms of brain cancer respectively. The company also holds a portfolio of drug delivery technologies designed to improve how medicines are released, dissolved, and directed to disease sites within the body. Founded in 2000 and headquartered in Cardiff, Wales, Biodexa works alongside partners Janssen and Melior to advance its research programs.
